Company:
News and Publications
FOR IMMEDIATE RELEASE
For more information contact:
Stephanie Stiles, Director of Marketing
phone: 781.273.5480
sstiles@putassoc.com
Putnam Associates, Strategy Consultants
to Pharmaceutical and Biotech Industries, Celebrates Its 20th Anniversary
with Book of Collected Essays
Essays highlight a variety of expert perspectives on changes
in competitive healthcare environment over past 20 years
May 11, 2009 -- In celebration of its 20th anniversary, Putnam Associates (www.putassoc.com), a strategy consulting firm to the pharmaceutical and biotechnology industries, has published The First Twenty Years Are the Hardest: Two Decades in Healthcare Strategy, a collection of essays from a cross section of experts in healthcare. Authors, including biopharmaceutical executives, venture capitalists, physicians, and seasoned strategy consultants, provide insights, background and recommendations regarding the complex and interwoven industries of healthcare. The book tackles a diverse set of business problems facing healthcare executives today, including: What is the optimal way to manage risk and innovation? How are pharmaceutical companies, big and small, dealing with globalization, threats from generics, and drying up pipelines? What has changed in the relationships between doctors, managed care, the government and biopharma, and how will they continue to evolve? What factors have contributed to rising healthcare costs, and how should they be addressed? Where does the future of this power struggle lie?
The book has an impressive list of contributors, all of whom write from different perspectives about their last twenty years in the biopharmaceutical industry and what they think the future holds.
Authors and titles of their essays include:
- Yoshihiko Hatanaka, Chief Strategy Officer and Chief Financial Officer, Astellas Pharma Inc., Tokyo, and former President and CEO of Astellas US: "Globalization of the Pharmaceutical Industry"
- Richard Zahn, former President of Schering Labs: "Myths, Perceptions, Progress, and Upheaval: Perspectives on the Pharmaceutical Industry, 1988-2008"
- John G. Freund, Founder and Managing Director, Skyline Ventures, Palo Alto: "From Biotechnology to Biopharmaceuticals: Changing Expectations and Valuations Over Twenty Years"
- Kurt Lewis, Global Sales Director, 3M Drug Delivery Systems, St. Paul: "The Changing Art of Persuasion: Evolution of the Biopharma Sales Rep"
- Brian Cohen MD, Director, Pratt Diagnostic Center, Tufts Medical Center, Boston: "Twenty Years of Change in Healthcare Delivery: An Interview with Dr. Brian Cohen"
- Kevin J. Gorman, Managing Partner, Putnam Associates: "Six Forces That Have Shaped the Past Twenty Years in Biopharmaceuticals"
[click here to open a PDF reprint. (file size ~ 3.5MB)] - Paul Bogorad, Ph.D., Senior Manager, Putnam Associates: "Assessing the Shifting Risks in Developing New Drugs: How Pharma Gets It Wrong"
[click here to open a PDF reprint. (file size ~ 2.5MB)] - Putnam Associates' team of authors: "Consolidation of Power and Fragmentation of Markets: The Evolution of Managed Care"
[click here to open a PDF reprint. (file size ~ 4.5MB)] - Putnam Associates' team of authors: "Generic Pharmaceuticals as Disruptive Innovation"
[click here to open a PDF reprint. (file size ~ 3.2MB)]
"Over the past twenty years we have participated along with our clients in some profound changes in the healthcare industries. Biotechnology has evolved from theory to a mainstay of cutting edge therapies. Diseases that were death sentences can now be treated as chronic conditions. Global level consolidation in the pharmaceutical industry has roiled competitive landscapes. Managed care has become the predominant form of health insurance in this country and has driven economic considerations of disease treatment to the forefront of decision making," states Kevin J. Gorman, Managing Partner, Putnam Associates.
Putnam Associates (www.putassoc.com) is a strategy consulting firm headquartered in Boston, founded in 1988, advising the pharmaceutical, biotechnology, diagnostics, and medical device industries on a global basis. Two decades of experience and focus in their industries enable them to create significant value for their clients. Creative and disciplined strategy development processes blend with deep market knowledge for one purpose: to help their clients succeed. The company’s partnership includes: Kevin J. Gorman, Managing Partner (BA, Boston College; MBA, Harvard Business School); Richard J. Tinsley, Partner (BA, Wharton School, University of Pennsylvania; MA, Stanford University; MBA, Stanford University); John A. Gordon, Partner (BA, summa cum laude, Tufts University; MBA, Harvard Business School); Eric C. Auger, Partner (BA, Providence College; MA, Boston University); and Domenick Bertelli, Partner (B.A. Harvard University; MBA, MIT Sloan School of Management).